EpilepsyGTx

Focalis

Focalis Bio develops gene therapies delivering engineered potassium channels to treat patients suffering from focal refractory epilepsy.

Corlieve Therapeutics

The company develops gene therapies for patients with refractory temporal lobe epilepsy and other severe neurological disorders.

GenEp

The company develops therapies targeting ion channel mutations to treat rare genetic and treatment-resistant epilepsies for patients with unmet medical needs.

Neurosciences

This company develops precision sodium channel therapeutics to treat patients with neurological conditions such as genetic epilepsy and chronic neuropathic pain.

Lario Therapeutics

This company develops precision medicines for patients with severe neurological disorders, including epilepsy and Parkinson’s disease.

Encoded Therapeutics

This biotechnology company develops precision genetic medicines for patients with severe neurological disorders, including Dravet syndrome.

Neurona Therapeutics

This company develops off-the-shelf regenerative neural cell therapies for patients with drug-resistant epilepsy and other chronic disorders of the central nervous system.

Neumirna Therapeutics

This biotechnology company develops microRNA-based therapies to treat patients with neurological disorders, including drug-resistant epilepsy and Parkinson's disease.